Europeans crack embryonic stem cells mystery
Europeans are driving research and technology, and their latest achievement is in discovering that embryonic stem cell properties are impacted by the laboratory conditions used to grow them. In their groundbreaking study, a European team of researchers evaluated embryonic stem cells grown in a pure undifferentiated state. The use of next generation sequencing technology enabled them to analyse gene expression (i.e. transcriptome) and chromatin modifications (i.e. epigenome). The study, presented in the journal Cell, was supported in part by four EU-funded projects: HEROIC, PLURISYS, EUROSYSTEM and ATLAS. The results pinpoint key differences between pure stem cells and embryonic stem cells grown in laboratory settings.
What allows embryonic stem cells to stay pluripotent? Researchers have been investigating this mystery for some time. Now a team of researchers from Germany, the Netherlands and the United Kingdom provide key answers, giving us information we need to know about how cells are controlled and what is the optimal way to grow them. The findings overturn previous reports suggesting that embryonic stem cells are both unstable and primed to differentiate. This information could help lead to the development of new and effective treatments.
Researchers from Nijmegen Centre for Molecular Life Sciences (NCMLS) and Radboud University in the Netherlands, as well as the Wellcome Trust Centre for Stem Cell Research, Stem Cell Institute and the University of Cambridge in the United Kingdom, and Technische Universität Dresden in Germany confirmed that transcriptome analysis allows scientists to identify which genes are turned on or off inside the cells. The gene's level of activity is also calculated through this method. Meanwhile, epigenome analysis provides researchers insight into how genes are controlled. This study went a step further by unlocking the mystery of how embryonic stem cells maintain their pluripotency, which experts describe as the capacity to make various cell types.
Through this study, researchers obtained key reference information in their quest to create a novel kind of human pluripotent stem cell equivalent to mouse embryonic stem cells. According to the team, the data represents the ground state of pluripotency.
Commenting on the results of the study, EUROSYSTEM ('European consortium for systematic stem cell biology') coordinator Austin Smith said: 'These findings show how much we are still learning about stem cells. They also point to an underlying difference between true embryonic stem cells isolated from mice and the currently available human stem cells which are less pure and more variable.'
HEROIC ('High-throughput epigenetic regulatory organisation in chromatin') received EUR 12 million under the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6). PLURISYS ('Systems biology approaches to understand cell pluripotency') is backed under the Health Theme of the Seventh Framework Programme (FP7) to the tune of EUR 2.97 million. Also supported under the Health Theme of the FP7 are EUROSYSTEM ('European consortium for systematic stem cell biology') with EUR 12 million and ATLAS ('Development of laser-based technologies and prototype instruments for genome-wide chromatin immunoprecipitation analyses') with almost EUR 3 million.
Henk Stunnenberg, head of one of the research groups that performed the study and coordinator of HEROIC, is now managing the BLUEPRINT ('A blueprint of haematopoietic epigenomes') project, which has received nearly EUR 30 million under the Health Theme of the FP7 to investigate epigenomes and their role in the underlying biological processes and mechanisms in health and disease.
Said Dr Stunnenberg: 'The epigenetic make-up - a layer of regulatory instructions on top of the genome - of the pure embryonic stem cells shows remarkable and unexpected features, in particular with respect to developmental genes. This forces a rethink of current models.'